The presence of myositis specific and myositis associated antibodies does not alter prognosis in IPF - Vienna 2024

Pulmonary fibrosis

Chair(s): Michelle Kam, Lurdes Planas Cerezales

Session type: Poster session

The presence of myositis specific and myositis associated antibodies does not alter prognosis in IPF

Robert Harrington

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Use of 6-min walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases

Umberto Zanini

Poster

Abstract

Monocytes, Mortality, and Disease Progression in IPF: A time-to-event analysis

Dominic Sykes

Abstract

Late Breaking Abstract - Evaluating the clinical potential of inhalation of umbilical cord mesenchymal stem cell (UC-MSC) exosomes in pulmonary fibrosis (PF) treatment.

Chen-en Chiang

Poster

Abstract

The prevalence of MUC5B variant and survival of patients with interstitial lung disease in Ireland: A multi-centre cohort study

Aoife Carolan

Poster

Abstract

Weight loss on nintedanib therapy in interstitial lung diseases (ILD)

Balamugesh Thangakunam

Poster

Abstract

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Nicol Bernardinello

Poster

Abstract

Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis is worse than its sporadic presentations.

Deborah Dos Reis Estrella

Poster

Abstract

Blood eosinophilia: a predictive marker of acute exacerbations in fibrotic interstitial lung disease?

Melanie David

Poster

Abstract

Distinct airway immune cell constitution in persistent post COVID-19 ILD.

Eliza Tsitoura

Poster

Abstract

Good health for patients with PPF: Insights from patient-led international focus groups

Silja Schenk

Poster

Abstract

A pilot HRCT follow-up study to test the feasibility of predictive efficacy of serum periostin in idiopathic pulmonary fibrosis

Mingtao Liu

Abstract

Evaluating the Progressive Factor's Impact on IPF Patients Treated with Antifibrotic Agents Over One Year

Yu-cheng Wu

Poster

Abstract

Time-Dependent Analysis of Calcium Channel Blocker Usage and Risk of Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis: A Nationwide Cohort Study

Jang Hye Jin

Poster

Abstract

Body composition phenotypes in IPF and their association with clinical outcomes

Hasan Ibis

Poster

Abstract

The presence of myositis specific and myositis associated antibodies does not alter prognosis in IPF

Robert Harrington

Poster

Abstract

PDGFR?-positive fibroblasts display a proinflammatory phenotype in infection-driven exacerbation of experimental lung fibrosis

Lara-kristin Steinmetz

Abstract

Effects of nerandomilast, a preferential PDE4B inhibitor, on metabolism of midazolam, a sensitive CYP3A substrate

Shilpa Madari

Poster

Abstract

Biomarkers in ICU-treated Covid-19 patients 4 and 10 months after discharge: evidence for persistent inflammation and remodeling

Dimitrios Kalafatis

Poster

Abstract

Immunological similarities between post-COVID19 lung sequelae and idiopathic pulmonary fibrosis

Sara Gangi

Abstract

Late Breaking Abstract - GTX-11 a new drug with anti-fibrotic effects in lung fibroblasts and in an ex vivo model

Carlos Esteban Machahua Huamani

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}